Kshirsagar RS, Eide JG, Harris J, Abiri A, Beswick DM, Chang EH, Fung N, Hong M, Johnson BJ, Kohanski MA, Le CH, Lee JT, Nabavizadeh SA, Obermeyer IP, Pandrangi VC, Pinheiro-Neto CD, Smith TL, Snyderman CH, Suh JD, Wang EW, Wang MB, Choby G, Geltzeiler M, Lazor J, Mitchell TC, Kuan EC, Palmer JN, and Adappa ND
Background: Sinonasal mucosal melanoma has poor survival despite multimodality treatment. While the impact of immunotherapy (IT) on metastatic cutaneous melanoma is well-defined, there are relatively little data on sinonasal mucosal melanoma., Objective: We sought to define immunotherapy outcomes in patients with sinonasal mucosal melanoma., Methods: A retrospective cohort study evaluated patients treated with IT during their overall treatment strategy for SNMM. Patient demographics, treatment, and survival outcomes were recorded., Results: 52 patients had IT treatment for SNMM from 2000 to 2022, with an average age of 69.1 ± 11.9 years. The most common treatment was surgery with radiation and IT ( n = 26, 50%). Most regimens consisted of a combination of Nivolumab and Ipilimumab ( n = 17, 32.7%) or pembrolizumab ( n = 14, 26.9%). 44.2% of patients experienced reported complications. Overall survival at 1-, 2-, and 5 years was 86.9%, 74.1%, and 39.1%, respectively., Conclusion: Approximately half of patients will have a local response following immunotherapy, but it is rare to have improvement at metastatic locations. Further research within our group will assess optimal timing and markers that are predictive of response., Competing Interests: Declaration of Conflicting InterestsThe authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: D.M.B. has received support from CF Foundation and from the International Society of Inflammation and Allergy of the Nose, consulting fees from Garner Health (equity), and honoraria from Rockpointe and Trinity Sciences. The other authors have no conflicts of interest to declare.